Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA (pregabalin) in Primary Generalized…
Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...
Read More...
